EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma

Merel T Stegenga iD, Evert F S van Velsen iD, Lindsey Oudijk iD, Frederik A Verburg, Tessa M van Ginhoven, Robin P Peeters iD, Marco Medici iD, W Edward Visser iD, Folkert J van Kemenade iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Merel T Stegenga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes, Adenocarcinoma, Follicular. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Risk factors for radioactive iodine (RAI)-refractory disease in follicular (FTC) and oncocytic thyroid carcinoma (OTC) are unknown.

Objective

The aim of this study is to identify clinical and histopathological risk factors for RAI-refractory disease in FTC and OTC patients, facilitated by an extensive histopathological revision.

Methods

All adult FTC and OTC patients treated at Erasmus MC (the Netherlands) between 2000 and 2016 were retrospectively included. The 2015 American Thyroid Association guidelines were used to define RAI-refractory disease. An extensive histopathological revision was performed applying the 2022 World Health Organization Classification using PALGA, the Dutch Pathology Databank. Logistic regression was used to identify risk factors for RAI-refractory disease, stratified by histological subtype.

Results

Ninety FTC and 52 OTC patients were included, of whom 14 FTC (15.6%) and 22 OTC (42.3%) patients developed RAI-refractory disease over a follow-up time of 8.5 years. RAI-refractory disease occurred in OTC after fewer cycles than in FTC (2.0 [interquartile range (IQR): 1.0-2.0] vs 2.5 [IQR: 2.0-3.75]), and it substantially decreased 10-year disease-specific survival, especially in OTC (46.4%; FTC 85.7%). In FTC, risk factors were higher age at diagnosis, pT3/pT4 stage, N1 stage, widely invasive tumors, and extrathyroidal extension. N1 stage and M1 stage were the strongest risk factors in OTC, rather than histopathological characteristics of the primary tumor.

Conclusion

To our knowledge, this is the first study that correlates clinical and histopathological risk factors with RAI-refractory disease in FTC and OTC, facilitated by a histopathological revision. In FTC, risk factors for RAI-refractory disease were foremost histopathological characteristics of the primary tumor, whereas in OTC presentation with lymph node and distant metastasis was associated with RAI-refractory disease. Our data can help clinical decision-making, particularly in patients at risk for RAI-refractory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesAdenocarcinoma, FollicularHumansFemaleMaleMiddle AgedRisk FactorsRetrospective StudiesAdultAgedAdenoma, OxyphilicNetherlandsFollow-Up Studies

Stichwörter der Autor:innen

follicular thyroid canceroncocytic thyroid carcinomaradioactive iodine refractory diseasethyroid neoplasms

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Erasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands.
  • Erasmus MC Bone Center, Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands.
  • Erasmus MC Academic Center for Thyroid Diseases, Department of Pathology, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands.
  • Erasmus MC Academic Center for Thyroid Diseases, Department of Radiology and Nuclear Medicine, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands.
  • Erasmus MC Academic Center for Thyroid Disease, Department of Surgery, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands.

ORCID-Profile: Merel T Stegenga, Evert F S van Velsen, Lindsey Oudijk, Robin P Peeters, Marco Medici, W Edward Visser, Folkert J van Kemenade

Zitieren

APA

Stegenga, M. T., van Velsen, E. F. S., Oudijk, L., Verburg, F. A., van Ginhoven, T. M., Peeters, R. P., Medici, M., Visser, W. E., & van Kemenade, F. J. (2024). Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae084

Vancouver

Stegenga MT, van Velsen EFS, Oudijk L, Verburg FA, van Ginhoven TM, Peeters RP, et al. Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae084

BibTeX
@article{Stegenga2024,
  author = {Stegenga, Merel T and van Velsen, Evert F S and Oudijk, Lindsey and Verburg, Frederik A and van Ginhoven, Tessa M and Peeters, Robin P and Medici, Marco and Visser, W Edward and van Kemenade, Folkert J},
  title = {Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae084}
}
Kostenlos starten →